2017
DOI: 10.1039/c7ra06499c
|View full text |Cite
|
Sign up to set email alerts
|

Kinetic resolution of (RS)-1-chloro-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol: a metoprolol intermediate and its validation through homology model of Pseudomonas fluorescens lipase

Abstract: Kinetic resolution of (±)-1-chloro-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol: a metoprolol intermediate and its validation through homology model of Pseudomonas fluorescens lipase.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 51 publications
0
2
0
Order By: Relevance
“…Use of DIPE (81 %), toluene (96.3 %) and n ‐butyl acetate (76.2 %) resulted in moderate to high percentage ee values in the product. Earlier reports have described the use of toluene in biocatalysis to prepare enantiopure β‐nitro alcohols, and lipases were reported to show high activity when toluene was used as a solvent in the kinetic resolution of β‐nitro alcohols and ( S )‐1‐chloro‐3‐[4‐(2‐methoxyethyl)phenoxy]propan‐2‐ol …”
Section: Resultsmentioning
confidence: 99%
“…Use of DIPE (81 %), toluene (96.3 %) and n ‐butyl acetate (76.2 %) resulted in moderate to high percentage ee values in the product. Earlier reports have described the use of toluene in biocatalysis to prepare enantiopure β‐nitro alcohols, and lipases were reported to show high activity when toluene was used as a solvent in the kinetic resolution of β‐nitro alcohols and ( S )‐1‐chloro‐3‐[4‐(2‐methoxyethyl)phenoxy]propan‐2‐ol …”
Section: Resultsmentioning
confidence: 99%
“…It is worth mentioning that among the most successful biocatalytic attempts are the lipase-catalyzed kinetic resolutions (KRs) of the respective racemates. In the last two decades, numerous highly efficient lipase-supported methods towards common non-racemic β-blockers, such as acebutolol, 7 alprenolol, 8 atenolol, 9 bufuralol, 10 bunitrolol, 11 carteolol, 12 carvedilol, 13 cloranolol, 14 esmolol, 15 labetalol, 16 metoprolol, 17 moprolol, 18 nifenalol, 19 pindolol, 20 practolol, 21 propranolol, 22 and satolol 22 b were elaborated. Despite these creative efforts invested in the biocatalytic syntheses of non-racemic β-blockers, the reported methods lack generality since any selected API of this class requires an independent and strictly dedicated synthetic strategy.…”
Section: Introductionmentioning
confidence: 99%